A5030967770- Myasthenia Gravis and Thymoma
- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
- RNA Interference and Gene Delivery
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Antifungal resistance and susceptibility
- Monoclonal and Polyclonal Antibodies Research
- Parkinson's Disease and Spinal Disorders
- Cancer Treatment and Pharmacology
- Cytokine Signaling Pathways and Interactions
- Ion channel regulation and function
- COVID-19 diagnosis using AI
- SARS-CoV-2 and COVID-19 Research
- Calcium signaling and nucleotide metabolism
- Inflammatory Myopathies and Dermatomyositis
- Artificial Intelligence in Healthcare and Education
- Antiplatelet Therapy and Cardiovascular Diseases
- Machine Learning in Healthcare
- Neuroscience and Neuropharmacology Research
- Cellular Mechanics and Interactions
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Inflammatory Biomarkers in Disease Prognosis
Heinrich Heine University Düsseldorf
2021-2025
Düsseldorf University Hospital
2021-2025
University Hospital Münster
2020-2021
Myasthenic crisis (MC) and disease exacerbation in myasthenia gravis (MG) are associated with significant lethality continue to impose a high burden on affected patients. Therefore, we sought determine potential predictors for MC as well identify factors affecting outcome.
Background Large language models (LLMs) have demonstrated impressive performances in various medical domains, prompting an exploration of their potential utility within the high-demand setting emergency department (ED) triage. This study evaluated triage proficiency different LLMs and ChatGPT, LLM-based chatbot, compared to professionally trained ED staff untrained personnel. We further explored whether LLM responses could guide effective Objective aimed assess efficacy associated product...
Background Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients. However, the current landscape hindered by paucity of comparative data that crucial treatment...
Objective Myasthenia gravis (MG) is the most common autoimmune disorder affecting neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, sparse. Both rituximab and eculizumab may be considered as therapeutic options refractory MG after insufficient symptom control by standard immunosuppressive therapies. Methods In this retrospective observational study, we included 57 rituximab-treated 20 eculizumab-treated patients with to...
Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission and severe disease courses. However, immunocompromised patients have not been included clinical trials real-world data point an attenuated immune response vaccines among with multiple sclerosis (MS) receiving immunomodulatory therapies. Methods We performed a retrospective study including 59 ocrelizumab (OCR)-treated MS who received vaccination. Anti-SARS-CoV-2-antibody titres, routine blood parameters...
The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming improve selection outcomes.
Cladribine is a synthetic deoxyadenosine analogue approved for the treatment of highly active relapsing multiple sclerosis (RMS). considered to be semi-selective immune-reconstitution therapy (IRT) that induces long-term remission following short course treatment. Here, we evaluated effect cladribine on immune cell reduction and reconstitution during first two years treatment.We analyzed our longitudinal, prospective, real-world cohort 80 cladribine-treated RMS patients from tertiary centers...
Introduction: The efficacy of anti-CD20 antibodies has significantly contributed to advancing our understanding disease pathogenesis and improved treatment outcomes in relapsing-remitting multiple sclerosis (RRMS). A comprehensive analysis the peripheral immune cell profile, combined with prospective clinical characterization, RRMS patients treated ocrelizumab (OCR) or ofatumumab (OFA) was performed further understand reconstitution following B-cell depletion. Methods: REBELLION-MS is a...
Einleitung: Neue Strategien zur Behandlung der Myasthenia gravis (MG) umfassen die Inhibition des Komplementfaktors C5 (C5IT) sowie den Antagonismus neonatalen Fc-Rezeptors (FcRn) und stellen vielversprechende Optionen für hochaktive Verläufe dar. Bisher verfügbare indirekte Vergleiche dieser Therapiemechanismen ergaben heterogene Resultate. Ziel Studie ist daher ein direkter Vergleich in einem Real World-Setting.
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding modulation in human system is required to improve responses and identify "off-target effects" shaping long-term outcomes. For this purpose, we studied cohort MG patients treated with either eculizumab (n = 10) or azathioprine as well treatment-naïve using combined proteomics metabolomics approach. This strategy confirmed known effects on terminal cascade....
Myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis (EAE) is the most commonly used animal model of multiple sclerosis. However, variations in induction protocol can affect EAE progression, and may reduce comparability data.In present study, we investigated influence different components for C57BL/6J mice on disease progression. In MOG35-55-induced chronic has been applied as a to challenge optimal pertussis toxin (PTx) dosing, while considering batch...
Myasthenia gravis (MG) is a prototypical autoimmune disease of the neuromuscular junction (NMJ). The study underlying pathophysiology has provided novel insights into interplay autoantibodies and complement-mediated tissue damage. Experimental myasthenia (EAMG) emerged as valuable animal model, designed to gain further insight test therapeutic approaches for MG. However, availability native acetylcholine receptor (AChR) protein limited favouring use recombinant proteins. To provide...
Abstract Myasthenia gravis is a chronic antibody-mediated autoimmune disease disrupting neuromuscular synaptic transmission. Informative biomarkers remain an unmet need to stratify patients with active requiring intensified monitoring and therapy; their identification the primary objective of this study. We applied mass spectrometry-based proteomic serum profiling for biomarker discovery. studied exploration prospective validation cohort consisting 114 140 anti-acetylcholine receptor...
Introduction Given the varying severity of coronavirus disease 2019 (COVID-19) and rapid spread Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection particularly vulnerable individuals has gained increasing attention during course pandemic. Methods We performed a 1-year follow-up study 51 ocrelizumab-treated patients with multiple sclerosis (OCR-pwMS) who received COVID-19 vaccination in 2021. retrospectively identified 37 additional OCR-pwMS, 42 pwMS...
Abstract Introduction Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the most common immune neuropathies leading to severe impairments in daily life. Current treatment options include intravenous immunoglobulins (IVIG), which are administered at intervals 4–12 weeks. Determination individual challenging since existing clinical scores lack sensitivity objectify small, partially fluctuating deficits patients. End-of-dose phenomena described by patients, manifested increased...
Aside from the established immune-mediated etiology of multiple sclerosis (MS), compelling evidence implicates platelets as important players in disease pathogenesis. Specifically, numerous studies have highlighted that activated promote central nervous system (CNS)-directed adaptive immune response early course. Platelets, therefore, present a novel opportunity for modulating neuroinflammatory process characterizes MS. We hypothesized well-known antiplatelet agent acetylsalicylic acid (ASA)...
Abstract Modulation of two-pore domain potassium (K 2P ) channels has emerged as a novel field therapeutic strategies they may regulate immune cell activation and metabolism, inflammatory signals, or barrier integrity. One these ion is the TWIK-related channel 1 (TREK1). In current study, we report identification validation new TREK1 activators. Firstly, used modified assay to perform high-throughput-screening Dose-response studies helped identify compounds with high separation between...
Chronic inflammation of skeletal muscle is the common feature idiopathic inflammatory myopathies (IIM). Given rarity disease and potential difficulty routinely obtaining target tissue, i.e., standardized muscle, our understanding immune signatures IIM spectrum remains incomplete. Further insight into topography needed to determine specific treatment targets according clinical immunological phenotypes. Thus, we used high-dimensional flow cytometry investigate phenotypes anti-synthetase...
Cladribine is a synthetic purine analogue that interferes with DNA synthesis and repair next to disrupting cellular proliferation in actively dividing lymphocytes. The compound approved for the treatment of multiple sclerosis (MS). can cross blood-brain barrier, suggesting potential effect on central nervous system (CNS) resident cells. Here, we explored compartment-specific immunosuppressive as well direct neuroprotective effects oral cladribine experimental autoimmune encephalomyelitis...